Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1Breast 1

Conditions

Neutropenia 4Febrile Neutropenia 3Breast Neoplasms 3Lymphoma 2Leukemia, Myeloid, Acute 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Choriocarcinoma 1Chemotherapy-induced Neutropenia 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Embryonal 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × pegylated granulocyte colony-stimulating factor × Clear all
NCT02005458 2018-07-17

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Xiamen Amoytop Biotech Co., Ltd.

Phase 2 Completed
80 enrolled
BreastClassical hematologyThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neutropenia, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡